Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines

Opinion statementDengue viruses (DENV) continue to circulate worldwide, resulting in a significant burden on human health. There are four antigenically distinct serotypes of DENV, an infection of which could result in a potentially life-threatening disease. Current treatment options are limited and rely on supportive care. Although one dengue vaccine is approved for dengue-immune individuals and has modest efficacy, there is still a need for therapeutics and vaccines that can reduce dengue morbidities and lower the infection burden. There have been recent advances in the development of promising drugs for the treatment of dengue. These include direct antivirals that can reduce virus replication as well as host-targeted drugs for reducing inflammation and/or vascular pathologies. There are also new vaccine candidates that are being evaluated for their safety and efficacy in preventing dengue disease. This review highlights nuances in the current standard-of-care treatment of dengue. We also discuss emerging treatment options, therapeutic drugs, and vaccines that are currently being pursued at various stages of preclinical and clinical development.

Automated summary

Dengue viruses (DENV) pose a significant burden on human health globally. Current treatment options for dengue are limited, but recent advances in the development of antiviral drugs and vaccines show promise. This review discusses the nuances in the standard-of-care treatment for dengue and highlights emerging treatment options and vaccine candidates at different stages of development.